压痛关节数与炎症活动:已确诊类风湿关节炎患者纵向研究
该纵向观察研究纳入209例已确诊类风湿关节炎(RA)并启动生物制剂治疗的患者,随访12个月。以压痛-肿胀关节计数差(TSJD)分组,发现以压痛关节为主者复合疾病活动评分(CDAS)和患者报告结局(PROMs)更高,但超声炎症评分更低。基线TSJD正向预测6个月CDAS,负向预测6个月和12个月超声评分。
要点
- 以压痛关节为主(TSJD>0)的RA患者CDAS和PROMs更高,但超声炎症评分更低。
- 基线TSJD正向预测6个月CDAS水平,负向预测6个月和12个月超声评分。
- TJC与PROMs高度相关(P<0.001),而与超声炎症相关性弱。
核心结论
- 以压痛关节为主的RA患者CDAS更高但超声定义的炎症水平更低,提示CDAS中纳入TJC可能对炎症活动提供误导信息。
研究设计与样本
- 观察性纵向研究,连续纳入209例启动bDMARD治疗的已确诊RA患者,在0、1、2、3、6和12个月进行临床、实验室和全面超声检查。
主要发现
- TJC仅与患者报告结局(PROMs)高度相关(P<0.001)。
- TSJD>0组在所有访视时CDAS和PROMs显著高于TSJD≤0组(P<0.001)。
- TSJD>0组实验室标志物和评估者全局VAS评分与TSJD≤0组相似,超声总评分显著更低(P<0.001-0.03)。
- 基线TSJD正向预测6个月时所有CDAS水平(P<0.001-0.019),负向预测6和12个月超声总评分(灰阶和能量多普勒)(P<0.001)。
临床怎么用
- 解读RA患者CDAS时需注意TJC可能受患者报告结局影响,以压痛关节为主而CDAS高者应结合超声评估炎症活动。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The tender joint count (TJC) is included in composite disease activity scores (CDAS) (the Disease Activity Score in 28 joints, the Clinical Disease Activity Index, and the Simplified Disease Activity Index). The impact of having predominantly tender joints was explored by use of the Tender-Swollen Joint Count Difference (TSJD), and ultrasound (US) provided a measure of joint inflammation. The current study aimed to explore the cross-sectional and longitudinal associations between the TSJD and a spectrum of outcome measures, including US scores in patients with established rheumatoid arthritis (RA) during follow-up and while receiving treatment with biologic disease-modifying antirheumatic drugs (bDMARDs). METHODS: This was an observational study of 209 patients with established RA consecutively included upon initiation of bDMARD treatment and followed-up with clinical, laboratory, and comprehensive US examinations at 0, 1, 2, 3, 6, and 12 months. Patients were categorized into 2 groups: those with predominantly tender joints (TSJD >0) and those with predominantly swollen joints (TSJD ≤0). Statistical analyses included Pearson's correlation coefficient, an independent samples t-test, and regression analyses. RESULTS: The TJC had high correlations only with patient-reported outcomes (PROMs) (P < 0.001). Levels from CDAS and PROMs were significantly higher (P < 0.001) at all visits in patients with TSJD >0 compared to those with TSJD <0. Laboratory markers and assessor's global visual analog scale scores were similar, and US sum scores were significantly lower (P < 0.001-0.03). The baseline TSJD positively predicted levels of all CDAS at 6 months (P < 0.001-0.019) but was a negative predictor of US sum scores (gray-scale and power Doppler) at 6 and 12 months (P < 0.001). CONCLUSION: Patients with predominantly tender joints had higher CDAS but lower levels of inflammation as defined by US. These findings indicate that inclusion of the TJC in the CDAS may contribute to misleading information about inflammatory activity.
引用
- Hammer HB, Michelsen B, Provan SA, et al. Tender Joint Count and Inflammatory Activity in Patients With Established Rheumatoid Arthritis: Results From a Longitudinal Study. Arthritis Care Res (Hoboken). 2020. PMID: 30474932. doi:10.1002/acr.23815
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。